HOOKIPA Pharma (HOOK) stock gains as Gilead Sciences agrees to acquire some of its antiviral assets for up to $10M. Read more ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration ...

Pegylated Interferons: Still a Major Player for the Treatment of Myeloproliferative Neoplasms Bispecific antibodies have ushered in a transformative era in treating non–small cell lung cancer (NSCLC), ...

Gilead Sciences (GILD) stock in focus as cancer drug Trodelvy outperforms chemotherapy in a Phase 3 trial for advanced triple ...

Gilead Sciences, Inc. GILD and GSK GSK are pioneers in the human immunodeficiency virus (HIV) treatment space. Gilead Sciences is a dominant player in the HIV market with market-leading treatments.

Gilead Sciences, Inc. (NASDAQ:GILD) plans to present over 20 research abstracts—spanning both Gilead and its cell therapy unit Kite—at two major medical conferences: the 2025 ASCO Annual ...

MARION COUNTY, Miss. (WDAM) - The Mt. Gilead/Improve Water Associations issued a system-wide, boil-water notice Monday. The notice affects all 915 customers the association serves, Mt. Gilead ...

ASML, Hess, and Celanese are among the names that are still cheap despite impressive earnings beats. We sell different types of products and services to both investment professionals and ...